DIMERIX ORD
Dimerix Reports Positive Data Supporting Action3 Study of DMX-200 to Treat Kidney Disease
Dimerix (ASX: DXB) has received final data analysis from the international PARASOL collaboration that reinforces support for proteinuria-based endpoints in its pivotal Phase 3 Action3 study on DMX-200 for the treatment of kidney disease. The multi-centre, randomised, double-blind, placebo-controlled study is testing the drug’s efficacy and safety in patients with focal segmental glomerulosclerosis (FSGS) who are […]
Dimerix and Amicus Therapeutics partner to commercialise kidney disease treatment DMX-200 in the US
Drug developer Dimerix (ASX: DXB) and US biopharmaceuticals company Amicus Therapeutics have entered into an exclusive US licence agreement for the commercialisation of Dimerix’s lead candidate DMX-200. The drug is under development in a pivotal Phase 3 study known as ACTION3 for the treatment of rare-but-fatal kidney disease focal segmental glomerulosclerosis (FSGS). Under the terms […]
Market wrap: ASX 200 closes below 7000-point mark despite a tentative recovery
The Australian share market took a couple of tentative steps in the upwards direction after a tough week in which the ASX 200 fell decisively below the important 7000-point mark. By the Friday close the index had limped upwards 0.4% or 28.7 points to 6,954.2 points after two positive days which followed on from a […]
Dimerix secures deal to commercialise DMX-200 for treatment of rare kidney disease
Drug development company Dimerix (ASX: DXB) has secured a licencing deal with Advanz Pharma Corp for the commercialisation of Dimerix’s Phase 3 drug candidate DMX-200 to treat focal segmental glomerulosclerosis (FSGS) kidney disease. The agreement will give Advanz exclusive rights to register and market the drug in the European Economic Area, UK, Switzerland, Canada, Australia […]